Segment Information by Division

January 1 to December 31

 (XLSX:) Download XLS

 

 

 

€ million

 

Silicones

 

Polymers

 

Biosolutions

 

Polysilicon

 

Other

 

Consoli-
dation

 

Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External sales

 

2,243.8

 

1,282.1

 

246.1

 

792.2

 

128.0

 

 

4,692.2

Internal sales

 

0.2

 

16.4

 

 

 

 

-16.6

 

Total sales

 

2,244.0

 

1,298.5

 

246.1

 

792.2

 

128.0

 

-16.6

 

4,692.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT

 

276.8

 

229.3

 

21.6

 

-147.8

 

-117.6

 

0.5

 

262.8

Depreciation, amortization and impairment losses/reversals

 

111.0

 

41.2

 

16.5

 

152.5

 

82.3

 

 

403.5

EBITDA

 

387.8

 

270.5

 

38.1

 

4.7

 

-35.3

 

0.5

 

666.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT includes: result from investments in joint ventures and associates

 

3.4

 

 

 

 

31.5

 

 

34.9

Impairment of fixed assets

 

-0.6

 

 

 

-0.1

 

-0.3

 

 

-1.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset additions1

 

96.9

 

35.6

 

19.9

 

24.9

 

47.1

 

 

224.4

Additions to financial assets

 

 

 

 

 

0.4

 

 

0.4

Asset additions

 

96.9

 

35.6

 

19.9

 

24.9

 

47.5

 

 

224.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets (Dec. 31)

 

1,644.3

 

673.5

 

223.1

 

1,040.8

 

3,368.9

 

-0.1

 

6,950.5

Liabilities (Dec. 31)

 

955.4

 

390.7

 

109.7

 

577.9

 

3,225.0

 

 

5,258.7

Net assets (Dec. 31)

 

688.9

 

282.8

 

113.4

 

462.9

 

143.9

 

-0.1

 

1,691.8

Investments in joint ventures and associates included in net assets (Dec. 31)2

 

45.0

 

 

 

 

554.5

 

 

599.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

60.2

 

32.2

 

5.7

 

21.3

 

37.2

 

 

156.6

Employees (Dec. 31)

 

5,076

 

1,540

 

764

 

2,180

 

4,723

 

 

14,283

Employees (average)

 

5,087

 

1,555

 

756

 

2,239

 

4,764

 

 –

 

14,401

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External sales

 

2,452.8

 

1,294.2

 

243.0

 

780.0

 

157.6

 

 

4,927.6

Internal sales

 

0.2

 

20.9

 

 

 

 

-21.1

 

Total sales

 

2,453.0

 

1,315.1

 

243.0

 

780.0

 

157.6

 

-21.1

 

4,927.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT

 

375.3

 

153.7

 

14.0

 

-1,012.9

 

-66.7

 

0.3

 

-536.3

Depreciation, amortization and impairment losses/reversals

 

103.2

 

40.5

 

17.1

 

1,069.8

 

89.1

 

 

1,319.7

EBITDA

 

478.5

 

194.2

 

31.1

 

56.9

 

22.4

 

0.3

 

783.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT includes: result from investments in joint ventures and associates

 

3.2

 

 

 

 

51.1

 

 

54.3

Impairment of fixed assets

 

-4.8

 

 

 

-760.0

 

 

 

-764.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset additions1

 

193.6

 

62.4

 

13.2

 

35.3

 

75.0

 

 

379.5

Additions to financial assets

 

 

 

 

 

6.6

 

 

6.6

Asset additions

 

193.6

 

62.4

 

13.2

 

35.3

 

81.6

 

 

386.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets (Dec. 31)

 

1,766.1

 

681.9

 

216.8

 

1,293.2

 

2,533.2

 

-0.2

 

6,491.0

Liabilities (Dec. 31)

 

929.2

 

331.4

 

97.4

 

584.9

 

2,519.1

 

 

4,462.0

Net assets (Dec. 31)

 

836.9

 

350.5

 

119.4

 

708.3

 

14.1

 

-0.2

 

2,029.0

Investments in joint ventures and associates included in net assets (Dec. 31)

 

42.7

 

 

 

 

597.7

 

 

640.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

65.0

 

33.9

 

6.4

 

30.0

 

38.0

 

 

173.3

Employees (Dec. 31)

 

5,267

 

1,630

 

754

 

2,333

 

4,674

 

 

14,658

Employees (average)

 

5,293

 

1,623

 

737

 

2,441

 

4,657

 

 

14,751

1

Intangible assets; property, plant and equipment; investment property; excluding right-of-use assets

 

The segment information by division is an integral part of the Notes to the Consolidated Financial Statements. For explanations of the key indicators, see Note 23.

2

Includes assets held for sale. The segment data by division are part of the notes.

todo Vorjahresvergleich